FOCUS magazine showcases a selection of our original resources. You can use the educational content featured in FOCUS to identify and reduce barriers that prevent people from accessing the medicines they need.

Contributor
He Ako Hiringa
16 June 2022
60 minutes to Delve

Explore your prescribing further with EPiC Reflect Diabetes. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

Contributor
He Ako Hiringa
14 April 2022
45 minutes to Delve

Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.

Contributor
Dr Ryan Paul
13 October 2021

Dulaglutide is available from 1 September, but do you know how to pronounce it? Listen to our quick guide for help.

Contributor
He Ako Hiringa
30 August 2021
15 minutes to Delve

From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.

Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.

Contributor
Brendan Duck, Ryan Paul
25 August 2021
15 minutes to Delve

When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk. 

Contributor
Brendan Duck, Ryan Paul
24 August 2021
1 minute to Read

When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin (updated July 2022) to find out more.

Contributor
He Ako Hiringa
17 August 2021
7 minutes to Read

Dulaglutide, a once-weekly injectable medicine, will soon be available for second-line treatment of type 2 diabetes. As most people with type 2 diabetes will require an injectable therapy at some stage, it is important to build acceptability early in the patient journey.

Contributor
Louise Roche Farmer
29 June 2021

This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.

Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.

Contributor
He Ako Hiringa
3 May 2021